{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Gallo L"],"funding":["National Institute of Allergy and Infectious Diseases","NCATS NIH HHS","NIDA NIH HHS","NIAID NIH HHS","NIMH NIH HHS","National Institute of Mental Health","National Institute on Drug Abuse"],"pagination":["166-174"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11652247"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["46(1)"],"pubmed_abstract":["There is high comorbidity of opioid use disorder (OUD) and chronic pain (CP), which is often addressed by prescribing buprenorphine (BUP). While BUP is effective in preventing overdose, it does not address the psychological aspects of OUD and CP comorbidity and treatment retention rates are as low as 50%. The Virtual Opioid use disorder Integrated Chronic Pain Treatment (VOICE) study (NCT05039554) is a novel effectiveness-implementation trial to test a 12-week virtual group Acceptance and Commitment Therapy (ACT) protocol and a care management smartphone application (app; Valera Health) on pain and opioid use in patients with OUD and CP receiving BUP. Using a 2 × 2 factorial design, participants (expected N = 280) are randomized into: ACT, Valera app, ACT + Valera, or Treatment as Usual ar"],"journal":["Substance use & addiction journal"],"pubmed_title":["A Randomized Trial Evaluating Acceptance and Commitment Therapy and Smart Phone Care Management Application to Augment Buprenorphine Therapy for Opioid Use and Chronic Pain."],"pmcid":["PMC11652247"],"funding_grant_id":["R01MH126821","R01MH128878","R01 MH120601","R01 DA054885","R01DA054885","R21MH126502","R21 MH126501","UM1 TR004400","P30AI124414","P30 AI124414","R21 MH121920","R21MH121920","RM1 DA055437","R01 MH128878","R01MH120601","RM1DA055437","R01 MH126821"],"pubmed_authors":["Bhambhani Y","Starrels J","Gallo L","Musicaro R","Bao Y","Rodgers CRR","Holzman S","Baker Z","Delgado GE","Stotts AL","Norton BT","Gabbay V","Lu T","Perez HR","Roske C","Richard JT","Deng Y"],"additional_accession":[]},"is_claimable":false,"name":"A Randomized Trial Evaluating Acceptance and Commitment Therapy and Smart Phone Care Management Application to Augment Buprenorphine Therapy for Opioid Use and Chronic Pain.","description":"There is high comorbidity of opioid use disorder (OUD) and chronic pain (CP), which is often addressed by prescribing buprenorphine (BUP). While BUP is effective in preventing overdose, it does not address the psychological aspects of OUD and CP comorbidity and treatment retention rates are as low as 50%. The Virtual Opioid use disorder Integrated Chronic Pain Treatment (VOICE) study (NCT05039554) is a novel effectiveness-implementation trial to test a 12-week virtual group Acceptance and Commitment Therapy (ACT) protocol and a care management smartphone application (app; Valera Health) on pain and opioid use in patients with OUD and CP receiving BUP. Using a 2 × 2 factorial design, participants (expected N = 280) are randomized into: ACT, Valera app, ACT + Valera, or Treatment as Usual ar","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jan","modification":"2026-06-06T20:01:12.63Z","creation":"2026-06-04T03:12:45.389Z"},"accession":"S-EPMC11652247","cross_references":{"pubmed":["39171416"],"doi":["10.1177/29767342241265178"]}}